Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 4/20 | 0.41 |
| ▸ | ABL1 | P00519 | 7/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6713924 | 0.92 | GPR35 (0.41) | GCGRABL1RXFP1NPC1RAB9A | |
| SCHEMBL6710151 | 0.90 | ROCK2 (0.40) | GCGRABL1NPC1RAB9ATRPV1 | |
| SCHEMBL6709012 | 0.85 | ABL1 (0.45) | GCGRABL1RXFP1NPC1RAB9A | |
| SCHEMBL6707646 | 0.84 | RXFP1 (0.45) | RXFP1NPC1RAB9AGRM4THRB | |
| SCHEMBL6707804 | 0.83 | MAPT (0.43) | RXFP1GRM4TP53SMN1; SMN2 | |
| SCHEMBL6707706 | 0.82 | GRM4 (0.44) | RXFP1NPC1RAB9AGRM4SMN1; SMN2 | |
| SCHEMBL6708839 | 0.82 | GRM4 (0.42) | RXFP1NPC1RAB9AGRM4 | |
| SCHEMBL6708004 | 0.81 | RXFP1 (0.41) | RXFP1GRM4SMN1; SMN2 | |
| SCHEMBL6714240 | 0.80 | RXFP1 (0.42) | RXFP1GRM4TP53 | |
| SCHEMBL6710017 | 0.80 | RXFP1 (0.45) | RXFP1GRM4THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | GCGR 2611/4885ABL1 344/4885RXFP1 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.